Phase I Dose Escalation Trial of Single Fraction Adjuvant Stereotactic Body Partial Breast irradiation (SB-PBI) For Early Stage Breast Cancer
Brief description of study
In this study, early-stage breast cancer patients will be receiving a single fraction (radiation dose) via FDA-approved Cyberknife technology. The main goal of this study is to identify the ideal single dose of level for treatment, and assess cosmesis (preservation and appearance of the breast).
Clinical Study Identifier: s18-01764
ClinicalTrials.gov Identifier: NCT02685332
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
